AI
By
Is Thermo Fisher’s $10B Q2 Surge the Inflection Point for AI-Powered Biopharma? How Will It Reshape the Life Sciences Landscape?
Key Highlights Financial Resilience and Strategic MarginsThermo Fisher Scientific’s Q2 2025 report showcases its fortress-like financial discipline. With…
Can IGC Pharma’s New AI Models Change Alzheimer’s Diagnosis and Drug Discovery for Millions?
New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings Key…
Can Cedars-Sinai’s CS Connect Revolutionize Virtual Care? 42,000 Patients Served, AI Outperforms Doctors in 77% of Cases, K Health Partnership Sets New Standard
Key Takeaways: AI helping doctors focus on care, not paperworkCedars-Sinai launched CS Connect to improve access to care…
Can hellocare.ai and Epic’s Native Integration Redefine AI-Driven Inpatient Care Across US Hospitals?
Key Takeaways Epic Integration Enhances Bedside Engagementhellocare.ai’s purpose-built virtual care device now supports Epic MyChart Bedside TV out…
Can Ambience Healthcare’s $243M Series C Push the AI Scribing Market Toward a $5B Future?
Key Highlights Record Funding and Unicorn StatusAmbience Healthcare, founded in 2020 in San Francisco, announced a $243 million…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
